CA3074054A1 - Mazindol treatment for heroin dependence and substance use disorder - Google Patents

Mazindol treatment for heroin dependence and substance use disorder Download PDF

Info

Publication number
CA3074054A1
CA3074054A1 CA3074054A CA3074054A CA3074054A1 CA 3074054 A1 CA3074054 A1 CA 3074054A1 CA 3074054 A CA3074054 A CA 3074054A CA 3074054 A CA3074054 A CA 3074054A CA 3074054 A1 CA3074054 A1 CA 3074054A1
Authority
CA
Canada
Prior art keywords
mazindol
drug
heroin
paired
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3074054A
Other languages
English (en)
French (fr)
Inventor
Alexander C. Zwyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NLS Pharmaceutics AG
Original Assignee
NLS 1 Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NLS 1 Pharma AG filed Critical NLS 1 Pharma AG
Publication of CA3074054A1 publication Critical patent/CA3074054A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3074054A 2017-09-07 2018-09-06 Mazindol treatment for heroin dependence and substance use disorder Pending CA3074054A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555469P 2017-09-07 2017-09-07
US62/555,469 2017-09-07
PCT/IB2018/001138 WO2019058172A1 (en) 2017-09-07 2018-09-06 MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES

Publications (1)

Publication Number Publication Date
CA3074054A1 true CA3074054A1 (en) 2019-03-28

Family

ID=64316589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3074054A Pending CA3074054A1 (en) 2017-09-07 2018-09-06 Mazindol treatment for heroin dependence and substance use disorder

Country Status (9)

Country Link
US (1) US11596622B2 (https=)
EP (1) EP3678661A1 (https=)
JP (1) JP7593619B2 (https=)
KR (1) KR20200085730A (https=)
CN (1) CN111343979A (https=)
BR (1) BR112020004506A2 (https=)
CA (1) CA3074054A1 (https=)
MX (1) MX2020002560A (https=)
WO (1) WO2019058172A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217987A (en) 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
FR2899476B1 (fr) 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
WO2009029308A1 (en) 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
JP2013523757A (ja) 2010-03-31 2013-06-17 スパーナス ファーマシューティカルズ インコーポレイテッド マジンドールの製剤
US9687445B2 (en) * 2012-04-12 2017-06-27 Lts Lohmann Therapie-Systeme Ag Oral film containing opiate enteric-release beads
JP6584745B2 (ja) 2014-04-09 2019-10-02 和久 前田 抗肥満薬の効果を向上させる組成物の製造方法。
ES2884973T3 (es) 2016-03-09 2021-12-13 Nls Pharmaceutics Ag Comprimido multicapa de mazindol de IR/SR y su utilización para el tratamiento del trastorno por déficit de atención/hiperactividad (ADHD)

Also Published As

Publication number Publication date
US11596622B2 (en) 2023-03-07
EP3678661A1 (en) 2020-07-15
US20210161865A1 (en) 2021-06-03
JP2020533295A (ja) 2020-11-19
MX2020002560A (es) 2020-07-13
WO2019058172A1 (en) 2019-03-28
BR112020004506A2 (pt) 2020-09-15
JP7593619B2 (ja) 2024-12-03
CN111343979A (zh) 2020-06-26
KR20200085730A (ko) 2020-07-15

Similar Documents

Publication Publication Date Title
KR101688996B1 (ko) 통증 치료에 있어서 트라마돌 및 셀레콕시브를 포함하는 조성물
WO2022023812A1 (en) Extended release 5-ht receptor agonists for neurological conditions
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
JP2002532393A (ja) エキソ−ｒ−メカミラミン製剤および治療におけるその使用
US6512009B1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
WO2020183455A1 (en) Cannabinoid combinations for treating low back pain
CN115916174A (zh) 用于预防应激诱导的恐惧、抑郁样和焦虑样行为的组合物和方法
MX2015002796A (es) Composiciones nootropicas para mejorar el funcionamiento de la memoria.
WO2019018247A1 (en) USE OF AMBROXOL TO IMPROVE AND / OR EXTEND THE LIFETIME IN GOOD HEALTH, LIFETIME AND / OR MENTAL ACUITY
AU2023336222A1 (en) Use of mdma for treatment of stress-related disorders
EP2872145B1 (en) Fused benzazepines for treatment of tourette's syndrome
MXPA05000791A (es) Compuestos de 1-fenil-2-dimetilaminometil ciclohexano para la terapia de sintomas depresivos, dolor e incontinencia.
CA3074054A1 (en) Mazindol treatment for heroin dependence and substance use disorder
JP2012500248A (ja) 不安障害の治療
CN111050800B (zh) 血清素3受体激动剂对疼痛的治疗
WO2010024717A1 (ru) Лиганд с широким спектром фармакологической активности, фармацевтическая композиция, лекарственное средство и способ лечения
EA051128B1 (ru) Медицинское применение даридорексанта
WO2011076363A1 (en) Morphinan-6-one compounds for the treatment or prevention of neurodegenerative diseases
HK40003594A (en) Methods of treating behavioral syndromes using pipradrol
HK1209336B (en) Fused benzazepines for treatment of tourette's syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230313

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240805

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240805

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240910

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240910

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250121

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250321

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250510

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250510

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250812

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260119

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260303